we-solve (beta)

Econ-267 · economics · Economics

Antibiotic innovation incentives

LLM status Open unverified

Statement

Original subject group: Health economics

Audit classification: Background; proposed extension. Prevented duplicate valuation of resistance health losses and separated payments from resource costs.

Definitions and precise research target

Editorial formalization. Consider developers of antibiotics for a prespecified set of resistant pathogens in European health systems. A policy $d\in\mathcal D$ is a fully specified combination of research grants, milestone prizes, subscription payments, and stewardship requirements; $\mathcal D$ is a finite feasible set. Let $A(d)$ be the number of qualifying antibiotics approved within ten years, $H(d)$ discounted patient health gained, $R(d)$ resistance burden after usage responses, and $K(d)$ discounted real public and private resource cost. For positive valuations $\lambda,\mu$, define \[d^*\in\arg\max_{d\in\mathcal D}E[\lambda H(d)-\mu R(d)-K(d)]\quad\text{subject to}\quad E[A(d)]\geq a_0,\] where $a_0$ is a stated minimum innovation target. Report infeasibility if no contract reaches the innovation target, and require finite expected objective terms. Model entry, scientific failure, information available to the payer, and manufacturer incentives under each contract. Specify which quantities can be estimated from existing programs and which require bounds or elicited scientific probabilities. Include cross-border resistance externalities and distinguish payments from resource costs. Ask whether revenue independent of sales can produce valuable innovation while preserving low appropriate usage. This is a proposed mechanism and quantitative design problem; the original policy review was not verified as explicitly posing this exact optimization problem.

A qualifying antibiotic has prespecified pathogen coverage, novelty, clinical effectiveness, and approval criteria. Define $A(d)$ as its approval count, $H(d)$ as quality-adjusted patient-years gained, and $R(d)$ as an additional resistance externality valued in declared units. If resistance already reduces $H$, do not value the same loss again in $R$: either define $R$ as a separate ecological/nonhealth damage or include all resistance health consequences in $H$ and omit $\mu R$. $K$ is real R&D, delivery and administration cost; grants and subscriptions are budget transfers and require a separate payer budget constraint. The menu includes contract terms and stewardship enforcement, not just names of instruments. With finite integrable feasible choices the optimizer exists. The substantive editorial task is estimating innovation, use and resistance responses under these contracts. All expectations use a stated baseline population and probability law. Identification means every admissible data-generating model with the same observed-data law yields the same displayed target; otherwise report the identified set. Exact equations, horizons and assumptions are editorial, rather than source-given canonical conjectures.

Variants and assumption changes

  1. Editorial sales-linked variant. Compare per-dose reimbursement and subscription at equal expected fiscal expenditure. Estimate use and resistance changes; equal budgets do not imply equal resource costs.
  2. Editorial international variant. Include low-income-country access and global resistance propagation. Compare coordinated and unilateral funding under stated spillover rules.

References and source audit

1. Review compares incentive options; exact innovation-constrained optimizer is editorial. Locator: Lancet Regional Health–Europe 33, 100705; Summary, p.1; author-repository PDF. PMC follow-ups met a challenge page; identical primary author-repository article inspected. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10403717/.
  1. Michael Anderson; Dimitra Panteli; Robin van Kessel; Gunnar Ljungqvist; Francesca Colombo; Elias Mossialos. 2023. Challenges and opportunities for incentivising antibiotic research and development in Europe. Lancet Regional Health–Europe 33, 100705; Summary, p.1; author-repository PDF. https://pmc.ncbi.nlm.nih.gov/articles/PMC10403717/. DOI: https://doi.org/10.1016/j.lanepe.2023.100705.

Common conventions: Source mathematical conventions

These conventions apply to each entry unless explicitly replaced.

Models and identification. A primitive model $m$ specifies all probability laws, feasible choices, information, equilibrium and measurement rules used by its target. The admissible class $\mathcal M$ is fixed independently of outcomes. If $P_O(m)$ is its observable probability law and $\tau(m)$ the target, its identified set at observable law $P$ is \[ \mathcal I_\tau(P)=\{\tau(m):m\in\mathcal M,\ P_O(m)=P\}. \] Point identification means that this set is a singleton. An empty set signals incompatibility of data and assumptions. Coordinate bounds need not describe the joint set. Bounds are sharp only if every retained target is attainable or arbitrarily approachable by compatible models. Finite bounds require explicit restrictions on unobserved quantities; unrestricted confounding, hidden wealth, extrapolation or arbitrary equilibrium selection can yield uninformative sets.

Causal interventions. A potential outcome $Y_i(p)$ is the outcome under a complete policy regime $p$, including timing, financing, information and market spillovers. The target population and units are fixed before treatment. With interference, use the complete assignment vector or a justified exposure mapping; individual no-interference notation alone cannot identify an economy-wide intervention. A difference of mean potential outcomes does not require the cross-world joint distribution. Conditioning on post-treatment migration, survival, enrollment or employment changes the estimand and needs separate justification.

Statistical statements. An estimator, confidence set, forecast or test specifies a sampling law, model class and loss/coverage criterion. Uniform $(1-\alpha)$-coverage means $\inf_{m\in\mathcal M}\Pr_m\{\tau(m)\in C_n\}\geq1-\alpha$, or an explicitly asymptotic version. The whole parameter space trivially has coverage, so informativeness requires a stated width, risk or power objective. A forecasting improvement is relative to a named benchmark, information set and evaluation population.

Equilibrium and optimization. An equilibrium comprises feasible plans, optimality, beliefs where needed, budget constraints and all market/resource clearing. The primitives or a stated benchmark define each correspondence $\mathcal E(p;m)$. Nonemptiness is assumed or proved, never inferred just from compact policy sets. A selected-equilibrium target uses a declared selection rule; a robust target quantifies over all permitted equilibria. Use suprema or infima unless attainment is established. An $\varepsilon$-optimal policy is feasible and within $\varepsilon$ of the finite optimum value. Report an empty feasible set separately.

Welfare and accounting. Normative utility, interpersonal normalization, social weights, numeraire, discounting and the use of public receipts are primitives. Behavioral utility need not coincide with the welfare criterion. Household welfare includes ownership income and rents once; adding profits again to compensating variation generally double-counts them. A monetary equivalent is defined by an explicit transfer and price convention, with monotonicity and range conditions. Average effects, mechanism contributions, transfers and welfare losses are different targets. Infinite sums require convergence and dynamic feasible plans require terminal or no-Ponzi conditions.

Source versions. A working-paper date, revision date and journal publication year are distinguished. A DOI for a journal version is not automatically the DOI of an earlier manuscript. Locators refer to the stated version and printed pages where specified. A metadata-only check does not verify a claim about a full-text conclusion. Every entry's source subsection narrows the provenance claim accordingly.

Statement licence: CC-BY-4.0 · Source file

Contributions 1

Econ-267-A1 · Exploration · LLM-generated · gpt 6 astra ultra ·

GPT 6 Astra Ultra attempt on Econ-267

Innovation and stewardship: an implementable antibiotic contract frontier

Catalogue problem: I18-263. Status: Unresolved. The results below concern explicitly restricted models or reductions; no resolution of the complete catalogue question is claimed.

Question and scope

The catalogue asks how a finite menu of antibiotic research contracts can maximize health benefits net of additional resistance damage and real costs, subject to a minimum expected approval count. The difficult quantities are the entry, research, use and resistance responses. Anderson et al. [anderson] review the institutional incentives; the optimization problem in the catalogue is an editorial formulation. The model below is a deliberately small mechanism with scientific failure and two different incentive constraints. It delivers an exact fiscal frontier, not empirical estimates of antibiotic innovation.

Primitives and timing

There is one potential developer and one ten-year research opportunity. Entry costs $f\geq0$ in real resources. Conditional on entry, unobservable effort $e\in[0,1]$ costs $ce^2/2$ and generates one qualifying approval with probability $e$. Failure gives no operating revenue. All agents are risk neutral; the developer has sufficient liquidity to pay research costs. The payer observes entry, approval and postapproval use, but not effort. Entry is verifiable, so an entry grant cannot be collected without paying $f$.

Conditional on approval, use $x\in[0,1]$ produces patient health $hx$, real delivery cost $dx^2/2$, and manufacturer operating profit \[ v(x)=mx-dx^2/2,\qquad m,d,h>0. \] Sales receipts $mx$ are transfers from users or insurers. They are not an extra social resource benefit. Let $x_m=\min\{m/d,1\}$ and $v_m=v(x_m)$. Assume $c>v_m$. Additional resistance damage is $rx^2/2$, where $r=r_D+r_F\geq0$ includes domestic and foreign damage. This damage excludes health losses already counted in $h$; otherwise the resistance term must be omitted or the health measure redefined.

A contract $(g,b,S,u)$ has nonnegative entry grant $g$, approval milestone $b$, subscription $S$, and use ceiling $u\in[0,x_m]$. The subscription is paid after approval exactly when $x\leq u$. The milestone is paid irrespective of use. Monitoring is perfect in this restricted model. Among equal-profit use choices the developer complies; among entry and nonentry at equal profit it enters. These rules matter at minimum payments. Expected payer expenditure is $g+e(b+S)$ on the compliance path, separate from the welfare criterion. Let $B$ be its upper bound.

Exact implementation costs

Theorem (Minimum-cost implementation): Fix a desired approval probability $e\in(0,1]$ and use $u\in[0,x_m]$. Under the preceding assumptions, a nonnegative-payment contract implementing entry, effort $e$ and use $u$ exists if and only if \[ ce\geq v_m. \] Among implementing contracts its minimum expected payer expenditure equals \begin{equation}\label{wsref-0-65-71-3a-66-69-73-63-61-6c} P(e,u)=\left(f-ce^2/2\right)_++e\{ce-v(u)\}. \end{equation} One minimizing contract is \[ S=v_m-v(u),\qquad b=ce-v_m,\qquad g=\left(f-ce^2/2\right)_+. \] For $e=1$, these formulas use the least reward that induces the upper effort boundary. The minimum is attained under the declared tie rules.
Proof: Since $v$ is increasing on $[0,x_m]$, the best compliant use is $u$, yielding approval-contingent revenue $b+S+v(u)$. The best unrestricted operating profit is $v_m$. A deviation that forfeits the subscription can therefore be deterred by, and for $u<x_m$ requires, \[ S+v(u)\geq v_m. \] For $u=x_m$ this condition reduces to $S\geq0$ and is also exact. Write $T=b+S+v(u)$. Conditional on compliance, effort maximizes $Te-ce^2/2$. Its unique optimum is $\min\{T/c,1\}$, since $T\geq0$. Thus an interior target requires $T=ce$, and a target $e=1$ requires $T\geq c$. Nonnegative $b$ and the use constraint imply $T\geq v_m$.

For an interior target, $b+S=ce-v(u)$ is consequently fixed. Maximized research profit before the grant and entry cost is $ce^2/2$. Participation requires $g\geq f-ce^2/2$, and nonnegativity gives the grant in the statement. The proposed split of $b+S$ satisfies both incentive constraints and implements the target.

At $e=1$, raising $T$ above $c$ increases contingent payment one-for-one, while it can reduce the necessary grant by at most one-for-one: the sum is \[ (f-T+c/2)_++T-v(u), \] which is nondecreasing in $T$. Its minimum over $T\geq c$ occurs at $T=c$. Since $c>v_m$, this reward is feasible. Formula (eq:fiscal) follows. If $ce<v_m$, the target is interior and the lower bound $T\geq v_m$ makes its effort incentive impossible. ∎

The positive-payment restriction produces an economically meaningful lower bound on effort: a grant or a subscription cannot remove the developer's opportunity to earn $v_m$ after success. Tighter stewardship requires a larger subscription, but it need not change total approval-contingent reward. Its implementation trades sales income for public payment.

Corollary (A fiscal cost of stricter stewardship): For fixed implementable $e$, $P(e,u)$ is nonincreasing in $u\in[0,x_m]$, and strictly decreasing whenever $v$ is strictly increasing between the two compared ceilings. An entry grant by itself does not change conditional effort in this model.
Proof: Only the term $-ev(u)$ in (eq:fiscal) varies with $u$. The grant is sunk when effort is chosen and hence drops out of its first-order comparison. ∎

Welfare frontier and a solved benchmark

Let $a_0\in(0,1]$ be the innovation target. If an implementing contract is used, expected approvals, health and additional resistance are respectively $e$, $ehu$ and $eru^2/2$. Expected real costs are $f+ce^2/2+edu^2/2$. For fixed declared weights $\lambda>0$ and $\mu\geq0$, write \[ V(u)=\lambda hu-(d+\mu r)u^2/2,\quad W(e,u)=eV(u)-ce^2/2-f,\quad e_0=\max\{a_0,v_m/c\}. \] The payer is evaluating the specified patient population and the declared domestic-plus-foreign externality. No manufacturer sales receipts or public subsidies are added to $W$.
Proposition (Reduction to two allocation variables): The best welfare attainable by the above nonnegative contracts is the maximum of $W(e,u)$ over \[ \mathcal F_B=\{(e,u):e_0\leq e\leq1,\ 0\leq u\leq x_m,\ P(e,u)\leq B\}. \] If this set is empty, the innovation-and-budget requirement is infeasible. Otherwise a maximum exists and Theorem Theorem (Minimum-cost implementation) implements it. Without a binding fiscal constraint an optimum is \[ u^*=\min\{x_m,\lambda h/(d+\mu r)\},\qquad e^*=\min\{1,\max\{e_0,V(u^*)/c\}\}. \] In particular, this displayed solution remains valid with budget $B$ whenever $P(e^*,u^*)\leq B$.
Proof: Every implementing contract yields an allocation in the displayed rectangle and spends at least $P(e,u)$. Conversely the minimum-payment contract implements each point of $\mathcal F_B$. The set is closed and bounded since $P$ is continuous; $W$ is continuous, proving attainment when nonempty. For each strictly positive $e$, maximizing $W$ over $u$ is equivalent to maximizing the strictly concave quadratic $V$. Its clipped stationary point is $u^*$. Holding this maximizer fixed leaves the concave quadratic $eV(u^*)-ce^2/2$, whose maximizer on $[e_0,1]$ is the stated projection. The constant entry cost affects welfare but not this conditional optimum because positive approval targets require entry. ∎

A finite administrative menu is handled by evaluating its implementable allocations and fiscal costs, rather than replacing the menu by the continuous optimum. The continuous result is an upper benchmark and a way to diagnose which menu restrictions are costly. If $r_F>0$ and all other primitives coincide, the unconstrained global use ceiling weakly falls relative to a payer omitting $r_F$. This follows directly from the formula for $u^*$; with a binding budget the same comparison need not survive because low use is fiscally expensive.

Identification and remaining work

Even observing $(e,u)$ under a contract does not identify the approval probability under another reward without a research-cost model. The quadratic coefficient $c$, fixed entry cost $f$, failure technology, and the number of viable projects are primitives here. They require data, experimental variation or bounds. Similarly $h$ and especially the cross-border coefficient $r_F$ are not inferred from observed antibiotic sales. Administrative program data can record grants, approval milestones, subscriptions and measured use; those observations alone do not identify the externality response.

Perfect use verification, one project, known parameters, no hidden scientific quality, adequate developer liquidity and a single approval date are substantial restrictions. Imperfect monitoring can break the minimum-subscription formula, and competing firms can change the marginal research return. An international equilibrium would also need financing shares and access choices. The results prove an implementability frontier and a constrained optimum for the declared mechanism only. The quantitative menu choice, resistance dynamics, and identification problem in the original catalogue remain unresolved.

Completion Estimate

40%

This is a post hoc, heuristic estimate for the full catalogue target. The attempt derives a minimum-payment antibiotic contract frontier jointly implementing research effort and stewardship, then characterizes feasible welfare allocations with a payer budget. Quantitative program choice still requires identified scientific, entry, use and resistance responses, imperfect monitoring, competing developers and international financing and access dynamics.

References

Go to contribution →